Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Giuseppe Procopio, ASCO 2018 – Sorafenib in renal cell carcinoma – the RESORT trial

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 12th 2018

Giuseppe Procopio from Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, Italy talks to us about the RESORT trial and limitations of using sorafenib in patients with metastatic renal cell carcinoma after radical resection of metastases.

1. What is the rationale for investigating radical resection of metastases followed by sorafenib in advanced renal cell carcinoma? (0:11)

2. Could you tell us a little about the RESORT study design? (1:15)

3. What were the findings of the study? (1:50)

4. Why do you think sorafenib has no effect on relapse-free survival? (3:17)

5. What will be the next steps in this clinical investigation? (4:06)

Speaker disclosures: Giuseppe Procopio serves on the advisory board for Bayer, Bristol-Myers Squibb, Ipsen, Novartis and Pfizer.

Filmed at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5 2018

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup